CDMO Lonza has announced that it is adding dry powder inhaler testing capabilities at its facility in Tampa, FL, USA for increased DPI development capacity. Lonza, which established a Center of Excellence for DPI particle engineering and formulation in Bend, OR, USA in 2020, said that the new laboratories in the Florida location will include capabilities for handling highly potent APIs and are expected to come online in June 2022.
In March 2022, Lonza announced that it had joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). In addition to CDMO services, Lonza also makes and markets DPI capsules since acquiring Capsugel in 2017. Lonza Capsugel launched the Zephyr line of DPI capsules in 2019.
Lonza Head of Respiratory Delivery Matthew Ferguson said, “The expansion of the inhalation offering, combined with the extensive experience of the Bend team, will serve to support clinical and commercial projects. The addition of these capabilities in Tampa will provide a seamless offering within the Lonza inhalation network. The offering can also benefit from the customizable Capsugel Zephyr inhalation capsule offering.”
Associate Director Product Development, Small Molecules, Jeff Williamson of Lonza Tampa, commented, “Increasing our capabilities in providing solutions for inhaled products will benefit our existing and future customers. The growth of our inhalation service network will ensure that our team continues to deliver solutions and support necessary for advancing dry powder inhaler products for pulmonary delivery that often face solubility and bioavailability challenges.”
Read the Lonza press release.
